Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats

Repaglinide (RPG), a monotherapy insulin secretagogue used to treat diabetes mellitus-type II yet, it suffers from poor water solubility and variable bioavailability (∼ 50%) due to hepatic first pass metabolism. In this study, 2FI I-Optimal statistical design was employed to encapsulate RPG into nio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouad, Shahinaze A., Teaima, Mahmoud H., Gebril, Mostafa I., Abd Allah, Fathy I., El-Nabarawi, Mohamed A., Elhabal, Sammar Fathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943253/
https://www.ncbi.nlm.nih.gov/pubmed/36803255
http://dx.doi.org/10.1080/10717544.2023.2181747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943253/
https://www.ncbi.nlm.nih.gov/pubmed/36803255
http://dx.doi.org/10.1080/10717544.2023.2181747

Ejemplares similares